What Happened to Peptides in 2023 - And Where Things Stand in 2026

In 2023 the FDA placed a range of widely used compounded peptides into Category 2, which made them ineligible for compounding under Section 503A. In 2026 an FDA advisory committee began reviewing several of those substances individually. This article covers what changed, what it meant for patients, and where the process stands now.

What Is a Peptide Ban - And Why Did It Happen in 2023?

Peptides are short chains of amino acids studied for applications ranging from anti-aging to muscle recovery.

Until 2023, most peptides compounded in 503A pharmacies fell under FDA Category 1 - substances that could be legally compounded for individual patient needs. The FDA then placed a number of widely used peptides into Category 2, which meant they could no longer be compounded under Section 503A except in narrow circumstances.

This policy shift created immediate problems.

Many patients had been using peptides like sermorelin, BPC-157, and thymosin alpha-1 for years through doctor-supervised care. The ban left them scrambling to find legal access, while black market suppliers filled the void with unregulated products.

For a detailed explanation of Category 1 vs. Category 2 distinctions, see our article "FDA Category 1 vs. Category 2 - What's the Difference?"

The 2023 Peptide Ban's Impact on Patients and the Market

The 2023 ban had three major consequences:

1. Legitimate access shrank: Only peptides that remained eligible for 503A compounding could still be prepared by compounding pharmacies. Category 1 status is not the same as FDA approval, but it is what determines compounding eligibility. This limited options for patients who had been using peptides under medical supervision.
2. Gray market exploded: Online vendors began selling research chemicals labeled as "peptides for human use," often without proper storage, documentation, or safety testing.
3. Medical confusion: Doctors suddenly had fewer options available, while patients faced conflicting advice about legality and safety.

The result? Chaos.

For more on the risks of gray-market peptides, including contamination and mislabeling, read "Gray-Market Peptides: What You're Really Getting."

Regulatory Timeline: 2023 to Present

How the Peptide Industry Adapted to the Ban

In response to the 2023 ban, three major trends emerged:

1. Legitimate compounding pharmacies: Facilities like those partnering with PeptidePrescript maintained compliance by focusing on FDA-allowed compounds and maintaining documentation standards.
2. Telehealth prescriptions: Platforms that verified patient-doctor relationships through proper licensing kept care accessible while navigating regulatory boundaries. Learn more about telehealth peptide prescriptions.
3. Research into new formulations: Scientists accelerated work on novel peptide formulations that might qualify under existing compounding regulations.

Meanwhile, the gray market thrived.

Why Peptide Compounding Is Being Re-examined in 2026

Several factors are commonly cited for the renewed regulatory attention:

1. Scientific argument: Advocates argue that some peptides have a body of safety data supporting case-by-case evaluation rather than blanket restriction.
2. Industry engagement: Compounding pharmacies and trade groups have pressed for clearer quality and documentation standards.
3. Patient demand: Patients who lost access have pushed for a legal route back, and that pressure is part of the public record around the review.

What this means in practice:

As of late July 2026, the advisory committee has voted to recommend six peptides for the 503A Bulks List, but those votes are non-binding and the FDA has not issued a final rule. Nothing has restored access yet, and there is no guarantee about which substances, if any, will ultimately become eligible for 503A compounding. Any future access would still require a prescription and a licensed compounding pharmacy.

For the current, dated status of this process, including which peptides an FDA advisory committee is reviewing for compounding eligibility, see our 2026 FDA peptide compounding review, which we update as the FDA publishes outcomes.

How the Current Review Works

Peptide compounding policy drew renewed federal attention in early 2026, and commentary at the time focused on the growth of the unregulated gray market after the 2023 restrictions. The mechanism that matters for access, however, is the FDA's own review process rather than any single announcement.

The Pharmacy Compounding Advisory Committee (PCAC) reviews Category 2 substances on a case-by-case basis. At its July 23-24, 2026 meeting it voted to recommend six peptides for the 503A Bulks List and rejected one. For the current, dated status of that process, see our 2026 FDA peptide compounding review.

The broader policy direction emphasizes three principles:

1. Evidence-based review: Each Category 2 substance gets individual evaluation based on available safety and clinical data, not blanket restrictions
2. Quality assurance: Compounding pharmacies must follow strict guidelines for sterility and potency testing under USP standards
3. Doctor oversight: Patients must be under the care of a licensed provider who can monitor their progress and adjust as needed

The PCAC review process is ongoing. No Category 2 peptides have been reclassified to Category 1 yet, but the review mechanism now exists where it didn't before.

How to Access Peptides Responsibly in 2026

With the regulatory environment stabilizing, patients have several options for responsible peptide care:

1. Telehealth platforms: Services like PeptidePrescript allow patients to connect with qualified providers who can determine if peptides are appropriate for their specific needs. See our pricing options.
2. 503A compounding pharmacies: These facilities produce peptides under strict FDA guidelines. Learn how your peptides are made.
3. Medical supervision: All patients should have regular lab work and follow-ups to ensure safe, effective treatment. Review lab work guidelines during your consultation.

The key? Work with legitimate providers.

For patients already using peptides, join our waitlist to learn about upcoming access to FDA-compliant compounded peptides through PeptidePrescript.

FAQ: The 2023 Restrictions and the 2026 Review

We've compiled answers to frequently asked questions about the regulatory changes and their impact on peptide care.

How did the 2023 ban affect existing patients?

Patients who had been using peptides for years suddenly faced limited options.

Many had to discontinue treatment or risk using products from unregulated sources. This highlighted the importance of having a licensed provider who could navigate the changing landscape.

What is different about the 2026 approach?

Rather than treating peptides as a single block, the Pharmacy Compounding Advisory Committee is reviewing substances individually.

That process is ongoing. Peptides that remain in Category 2 are still not eligible for 503A compounding, and a review does not by itself change what a pharmacy may prepare.

How can I ensure my peptides are safe and legal?

Look for three key factors:

• Prescription from a licensed provider who understands peptide care
• Compounding by an FDA-registered 503A pharmacy
• Proper documentation including sterile manufacturing and potency testing

Will peptides be available through insurance programs?

Currently, most insurance plans don't cover compounded peptides.

Whether that changes in the future would depend on FDA decisions and on individual insurer policies, neither of which can be predicted here.

What about peptides still in Category 2?

Some peptides remain in Category 2 due to insufficient clinical evidence or safety concerns.

Patients should work with their providers to explore alternatives if their preferred compound isn't available.

The Future of Peptide care

The 2023-2026 regulatory journey underscores the importance of responsible peptide use.

The 2023 restrictions were disruptive, and the case-by-case review that followed is still in progress. Commonly discussed possibilities for the years ahead include:

• Additional peptides being studied in formal clinical trials
• Continued debate over insurance treatment of compounded medications
• Greater standardization of compounding practices
• Increased public awareness about the difference between research chemicals and pharmacy-compounded preparations

Getting Started with Peptide care in 2026

If you're considering peptide care, here's how to approach it responsibly:

1. Consult a qualified provider: Look for doctors who specialize in peptide care and maintain proper licensing in your state.
2. Review lab results: Most providers will require baseline blood work to determine if peptides are appropriate for your specific needs.
3. Choose an FDA-compliant pharmacy: Verify that your compounding pharmacy is registered with the FDA and follows 503A standards.
4. Monitor your progress: Ongoing care typically involves regular follow-ups, which are determined under medical supervision.

PeptidePrescript offers a complete solution for patients seeking responsible peptide care.

Our platform connects you with licensed providers and 503A compounding pharmacies. Explore our catalog of available peptides and join the waitlist to hear about access at launch.